AI is now embedded in systematic review and evidence synthesis workflows across pharma, medical devices, CROs, and academia. But most teams haven’t fully mapped what that means for their copyright obligations — and the gap between assuming compliance and knowing it is increasingly difficult to ascertain.

We’re hosting a webinar with Elsevier to close that gap.

Harpreet Singh Riat, Director, Technical Consulting, Advanced Data Solutions at Elsevier and Hans-Peter Meulekamp, Director of Business Development, Europe at DistillerSR will walk through the copyright landscape as it applies to evidence synthesis today — from subscription rights and Open Access licensing to the specific questions raised by AI-assisted extraction.

What You’ll Learn

• What’s the business case for copyright-compliant AI in third-party systems
• What it actually means to “use” an article in a systematic review under current copyright terms with third-party systems – key barriers and opportunities
• When AI-assisted extraction stays within standard subscription terms, and when it requires additional licensing
• How to leverage systematic reviews using copyright-compliant AI